- Will CAR-NK Cancer Therapy Surpass High-Cost CAR-T Immunotherapy?
- What is the role of Platelet Dynamics in Cancer Progression?
- Biomarkers can detect rapid aging of organs and disease risks
- Avoiding “Off-Target” Effects: Researchers Enhance the Safety of Future mRNA Therapies
- Japan: Sales Halted for ‘Cannabis Gummies’ as Health Issues Mount
- Evaluation of the carcinogenicity of organic fluorine compounds raised by WHO subsidiary
The look back at new drugs approved by FDA in 2021
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
- WHO Requests More Information from China on Pediatric Clustered Pneumonia
- First Chinese PD-1 Cancer Drug 30 Times More Expensive in U.S. than in China
- Cardiovascular Diseases Linked to COVID-19 Infections
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
The look back at new drugs approved by FDA in 2021.
In 2021, the U.S. Food and Drug Administration ( FDA ) approved more than 50 new drugs, approaching an all-time high in 2018 and matching 2020.
The FDA now approves twice as many drugs each year as it did 15 years ago, which is certainly a sign of scientific progress, but it is also a sign of the growing leniency of regulators, who have grown closer to industry.
Rapid approvals for new treatment options in their various forms are the new normal in regions of unmet need.
They account for about 70% of all approved new drugs.
Oncology drugs once again dominated the expedited and routine approval lists, with 8 of the 20 cancer drug approvals being simultaneously submitted and reviewed in other countries through the FDA-coordinated Orbis program.
Many drugs are the “first”
The 2021 approvals are full of “first” that hit a new target or provide the first treatment option for a disease subtype or cancer mutation.
In the drug discovery world, one of the most exciting approvals has been for Amgen’s Lumakras ( sotorasib ), a small molecule capable of targeting previously thought untreatable targets.
Lumakras inhibits the G12C mutant of KRAS protein, a GTPase that switches between activated ( GTP-bound ) and inactive ( GDP-bound ) conformations and is associated with many cancers.
KRAS G12C is the most commonly mutated subtype in non-small cell lung cancer ( NSCLC ).
Lumakras prevents cell proliferation by covalently binding Cys12 residues near the inducible allosteric switch pocket on KRAS, locking it in an inactive state.
The strong pace of approvals for genetically defined diseases has continued, with two firsts for non-small cell lung cancer patients with epidermal growth factor receptor ( EGFR ) exon 20 mutations.
Janssen’s first bispecific antibody targeting EGFR and cMET, Rybrenvant ( amivantamab vmjw ), and Takeda’s first oral small-molecule selective kinase inhibitor, Exkivity ( mobocertinib ), both received accelerated approval for disease progression following platinum-based chemotherapy of patients; this mutation is estimated to be present in 2-3% of non-small cell lung cancers.
More rare diseases, such as Duchenne muscular dystrophy, also continue to make breakthroughs.
In 2021, the FDA approved Sarepta’s Amondys45 ( casimersen ), a phosphodiamidomorpholine antisense oligonucleotide that skips exon 45 in 8% of patients with dystrophin mutations.
The company’s two other DMD drugs previously approved, Exondys51 ( eteplirsen ) and Vyondys53 ( golodirsen ), for a small number of patients with deletions in exons 51 and 53, respectively, were also approved on an accelerated basis.
Research on complement system proteins and effectors is also deepening, which drives drug development for other inflammatory and immune-related diseases.
ChemoCentryx’s Tavneos ( avacopan ), a small molecule that selectively inhibits the complement factor 5a ( C5a ) receptor, is approved in the U.S. and Japan as a supplement to standard glucocorticoid therapy for the treatment of severe active antipsychotics neutrophil cytoplasmic autoantibody ( ANCA )-associated vasculitis, a rare inflammatory disease.
In 2021, Apellis’ peptide drug Empaveli ( pegcetacoplan ) becomes the first C3 modulator approved for paroxysmal nocturnal hemoglobinuria, a rare blood disorder in which defective red blood cells are compromised by the immune system s attack.
Empaveli was more effective at increasing hemoglobin than Alexion’s C5-targeting monoclonal antibodies Soliris ( eculizumab ) and Ultomiris ( ravulizumab ).
This is because C3 is more important to the immune system complement cascade than downstream C5 proteins: C3 controls both extravascular and intravascular hemolysis, whereas C5 is only involved in intravascular hemolysis.
In November, another peptide drug, BioMarin’s Voxzogo ( vosoritide ), became the first approved to treat achondroplasia, the most common form of dwarfism .
Patients with achondroplasia have an overactive fibroblast growth factor receptor 3 ( FGFR3 ) gene, which inhibits bone formation.
Voxzogo is an analog of C-type natriuretic peptide, which binds to natriuretic peptide receptor B and inhibits the action of FGFR3, thereby stimulating bone growth.
Other first approvals in 2021 have broader health implications. In June, Novo Nordisk’s Wegovy ( semaglutide 2.4 mg ) became the first FDA-approved obesity drug to show efficacy equivalent to bariatric surgery, combined with diet and exercise, resulting in an average of 15 percent weight loss.
Biosimilars and Monoclonal Antibodies
Two biosimilars approved in 2021 could also have a huge impact on public health: Biocon’s Semgle ( insulin glargine ), a generic of Sanofi’s Lantus, and Boehringer Ingelheim’s antibody Cyltezo, a generic of AbbVie’s rheumatoid arthritis treatment The drug Humira.
Both drugs are designated as interchangeable, meaning that the original drug prescription can be automatically filled with inexpensive biosimilars without the intervention of the prescribing physician.
In 2021, the third biosimilar from Samsung Biopis and Biogen, Byooviz ( ranibizumab nuna ), becomes the first biosimilar approved for ophthalmology in the US and EU, a generic version of Roche’s Lucentis drug for wet age-related macular degeneration .
In terms of monoclonal antibodies, GlaxoSmithKline’s programmed cell death receptor-1 ( PD-1 ) blocker Jemperli ( dostarlimab gxly ) was approved for mismatch repair deficient ( dMMR ) recurrent or advanced endometrial cancer.
dMMR mutations are believed to be present in approximately 14% of solid tumor cancers in the United States.
Jemperli, the seventh PD-1 blocker, was hit in late 2020 by delays in COVID-19-related field tests, but the drug still benefits from the fast-track typical in cancer treatment.
Antibody drugs such as Jemperli will account for one-fifth of total FDA approvals in 2021; biologics as a whole will account for less than 40% of those approvals. Innovators continue to complement their valuable antibody franchises with convenient antibody formulations and delivery mechanisms.
Roche’s twice-yearly eye implant Susvimo ( ranibizumab ) was approved for wet age-related macular degeneration just a month after Samsung and Biogen’s Byooviz.
Antibodies continue to slowly expand into cardiovascular disease in 2021 with the approval of Regeneron’s Evkeeza ( evinacumab dgnb ) to treat homozygous familial hypercholesterolemia. Evkeeza is the first antibody to bind and block angiopoietin-like 3 ( Angplt3 ), which plays a role in lipid metabolism.
Meanwhile, antibody drug conjugates ( ADCs ) have come of age after a shaky history, with two more approvals in 2021 following a 2020 harvest. ADC Therapeutics’ Zynlonta ( loncastuximab tesirine ) became the tenth ADC in April and the first to target the cell surface antigen CD19 with a payload of pyrrolizumab for the treatment of diffuse large B-cell lymphoma. Seagen and Genmab’s Tivdak ( tisotumab-vedotin ) is the first tissue factor ( TF )-targeted ADC drug; it is approved for recurrent or metastatic cervical cancer.
CAR-T cell therapy
In 2021, the first chimeric antigen receptor ( CAR )-T cell therapy targeting targets other than CD19 will be available. Bristol-Myers Squibb ( BMS ) and Bluebird Bio’s Abecma ( idecabtagene Vicluel ) targets B cell maturation antigen ( BCMA ), a protein expressed by most multiple myeloma cells.
Abecma was approved for relapsed or refractory multiple myeloma after at least four treatments, based on a single-arm study of 127 patients.
Add to that February approval of BMS’ Breyanzi ( lisocabtagene-Maraluecel ), which targets CD-19 for diffuse large B-cell lymphoma, and there are five CAR-T cell therapies approved in the U.S. in 2021.
CAR-T therapy offers a treatment option for B-cell lymphoma and leukemia patients who have failed alternative therapies, with potential long-term benefits while avoiding aggressive chemotherapy. But their complex, highly individualized manufacturing process and high price limit their applications.
Currently, CAR-T cell therapy benefits only a few hundred patients. Some developers are looking to reduce production time and improve the tolerability and convenience of next-generation therapies, including allogeneic CAR-T and CAR-NK cells. However, cost remains a significant barrier to widespread use of this therapy.
1. Fresh from the biotech pipeline: too much, too fast? Nat Biotechnol. 2022; 40(2): 155–162.
The look back at new drugs approved by FDA in 2021.
(source:internet, reference only)
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.